BACKGROUND: More than one-third of people in the United States with hepatic C virus (HCV) infection pass through the correctional system annually. Data are lacking on outcomes of treatment with pegylated interferon plus ribavirin (PEG-RBV) in correctional settings. METHODS: During 2002-2006, we analyzed patients in the Connecticut Department of Correction who received PEG-RBV. We assessed the rates of sustained virological response, hospitalization, and use of medications to treat psychiatric disorders and anemia. RESULTS: Of 138 treatment-naive patients referred for treatment, 68 (49%) were approved. Overall, sustained virological response occurred in 47.1% of patients (for HCV genotype 1, 43.1%; for HCV genotypes 2 and 3, 58.8%). Only 9 patients (13%) discontinued treatment because of adverse effects. Multiple regression analysis revealed that not achieving a sustained virological response was correlated with HCV genotype 1 infection plus cirrhosis (adjusted odds ratio, 12.9; 95% confidence interval, 1.1-148) and baseline major depression (adjusted odds ratio, 3.4; 95% confidence interval, 1.01-11.6), but not with HIV infection, a baseline HCV RNA level >or=400,000 IU/mL, or black race. Compared with baseline, the rate of prescription of a new mood stabilizer (2.2 vs. 0.8 prescriptions per person-year) or an opioid (1.8 vs. 0.5 prescriptions per person-year) was higher during treatment, whereas there was no change in the rate of prescription of benzodiazepines and antipsychotic medications. CONCLUSIONS: These results support the feasibility and clinical effectiveness of PEG-RBV for the treatment of chronic HCV infection in correctional facilities.
BACKGROUND: More than one-third of people in the United States with hepatic C virus (HCV) infection pass through the correctional system annually. Data are lacking on outcomes of treatment with pegylated interferon plus ribavirin (PEG-RBV) in correctional settings. METHODS: During 2002-2006, we analyzed patients in the Connecticut Department of Correction who received PEG-RBV. We assessed the rates of sustained virological response, hospitalization, and use of medications to treat psychiatric disorders and anemia. RESULTS: Of 138 treatment-naive patients referred for treatment, 68 (49%) were approved. Overall, sustained virological response occurred in 47.1% of patients (for HCV genotype 1, 43.1%; for HCV genotypes 2 and 3, 58.8%). Only 9 patients (13%) discontinued treatment because of adverse effects. Multiple regression analysis revealed that not achieving a sustained virological response was correlated with HCV genotype 1 infection plus cirrhosis (adjusted odds ratio, 12.9; 95% confidence interval, 1.1-148) and baseline major depression (adjusted odds ratio, 3.4; 95% confidence interval, 1.01-11.6), but not with HIV infection, a baseline HCV RNA level >or=400,000 IU/mL, or black race. Compared with baseline, the rate of prescription of a new mood stabilizer (2.2 vs. 0.8 prescriptions per person-year) or an opioid (1.8 vs. 0.5 prescriptions per person-year) was higher during treatment, whereas there was no change in the rate of prescription of benzodiazepines and antipsychotic medications. CONCLUSIONS: These results support the feasibility and clinical effectiveness of PEG-RBV for the treatment of chronic HCV infection in correctional facilities.
Authors: Kathleen E Corey; Andrew S Ross; Alysse Wurcel; Julian Schulze Zur Wiesch; Arthur Y Kim; Georg M Lauer; Raymond T Chung Journal: Clin Gastroenterol Hepatol Date: 2006-08-22 Impact factor: 11.382
Authors: Annelies S Zinkernagel; Viktor von Wyl; Bruno Ledergerber; Martin Rickenbach; Hansjakob Furrer; Manuel Battegay; Bernard Hirschel; Philip E Tarr; Milos Opravil; Enos Bernasconi; Patrick Schmid; Rainer Weber Journal: Antivir Ther Date: 2006
Authors: John Farley; Shawn Vasdev; Benedikt Fischer; Emma Haydon; Jürgen Rehm; Theresa A Farley Journal: Am J Public Health Date: 2005-08-30 Impact factor: 9.308
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: Jason Grebely; Krista Genoway; Milan Khara; Fiona Duncan; Mark Viljoen; Doug Elliott; Jesse D Raffa; Stanley DeVlaming; Brian Conway Journal: Int J Drug Policy Date: 2007-04-27
Authors: Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill Journal: Ann Intern Med Date: 2004-03-02 Impact factor: 25.391
Authors: Curt G Beckwith; Ann E Kurth; Lauri Bazerman; Liza Solomon; Emily Patry; Josiah D Rich; Irene Kuo Journal: Am J Public Health Date: 2015-01 Impact factor: 9.308
Authors: Jaimie P Meyer; Javier Cepeda; Johnny Wu; Robert L Trestman; Frederick L Altice; Sandra A Springer Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: John T Nguyen; Josiah D Rich; Bradley W Brockmann; Fred Vohr; Anne Spaulding; Brian T Montague Journal: J Urban Health Date: 2015-08 Impact factor: 3.671
Authors: Tianhua He; Kan Li; Mark S Roberts; Anne C Spaulding; Turgay Ayer; John J Grefenstette; Jagpreet Chhatwal Journal: Ann Intern Med Date: 2015-11-24 Impact factor: 25.391